Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

According to the International Agency for Research on Cancer, there were 64,611 new cases and 57,727 deaths in India alone in 2022. The incidence of stomach cancer has been rising, with over 40% of ...

Doctors have rejected Navjot Singh Sidhu’s claims that his wife was completely cured of stage 4 terminal cancer following a curated diet, despite being given only a 3 per cent chance of survival.

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Brain cancer originates in the brain and consists of brain cancer cells. But brain metastases from lung cancer occur when cancer cells break off from the tumor in the lungs and enter the ...